1. Optimizing Cardiac Delivery of Modified mRNA
Nishat Sultana, Ajit Magadum, Yoav Hadas, Jason Kondrat, Neha Singh, Elias Youssef, Damelys Calderon, Elena Chepurko, Nicole Dubois, Roger J. Hajjar, Lior Zangi 
Molecular Therapy 
Volume 25, Issue 6, Pages (June 2017)
DOI: /j.ymthe
Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions

2. Figure 1
Optimizing ModRNA Modification to Increase Translation and Expression Kinetics in Vitro and In Vivo
Luc mRNA expression was compared between mRNA with or without nucleotide modifications (unmodified), using the IVIS imaging system, in rat neonatal CMs in vitro or CFW mouse heart in vivo. The nucleotide modifications tested were as follows: 100% replacement of uridine by 2-Thiouridine-5′-Triphosphate (2-thio ψU) or by 1-Methylpseudouridine-5′-Triphosphate (1-mψU) or 100% replacement of uridine by Pseudouridine-5′-Triphosphate and cytidine by 5-Methylcytidine-5′-Triphosphate (ψU + 5mC). (A and B) Representative images of transfected (with RNAiMAX) neonatal CMs or mice. Images were taken 24 hr post-transfection with 2.5 μg/well in a 24-well plate or intramyocardial injection with 100 μg modified or non-modified Luc mRNA, respectively. (C and D) Kinetics or pharmacokinetics of modified or non-modified Luc mRNA in vitro or in vivo, respectively. (E and F) Efficient translation of Luc modRNA with different nucleotide modifications. Total Luc signal was measured over 5 or 10 days post-transfection in vitro or in vivo, respectively. Results represent two independent experiments with n = 2 or n = 3 (total n = 5 wells or mice; ****p < , one-way ANOVA with Bonferroni post hoc test).
Molecular Therapy  , DOI: ( /j.ymthe )
Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions

3. Figure 2
Optimizing Vehicle and ModRNA Dose for CM Transfection In Vitro
Rat neonatal or hPSC-derived CMs were isolated and plated onto 24-well tissue culture plates. Different transfection regents were used to transfect the CMs with 2.5 μg nGFP modRNA (1-mψU)/per well. Then 18 hr post-transfection, cells were fixed and stained for actinin (red) and GFP (green). ImageJ was used to calculate the number of nGFP+ and Actinin+ cells in each well. (A and B) Representative images of transfected rat neonatal CMs (A) or hPSC-derived CMs (B) with RNAiMAX-nGFP modRNA complex 18 hr post-transfection. (C and D) Quantification of transfection efficiency of rat neonatal (C) or hPSC-derived CMs (D) using different transfection reagents. (E and F) Optimal doses per well were tested using optimal transfection reagent (RNAiMAX) using different doses of nGFP in rat neonatal CMs (E) or in hPSC-derived CMs (F). (G–J) FACS analysis was used 18 hr post-transfection with RNAiMAX and different nGFP modRNA doses to measure median GFP intensity and cell death (percentage Annexin V of viable cells) for rat neonatal CMs (G and I) or hPSC-derived CMs (H and J), respectively. Results represent two independent experiments with n = 3 wells (*p < 0.05 and ***p < 0.001, one-way ANOVA with Bonferroni post hoc test; scale bar, 10 μm).
Molecular Therapy  , DOI: ( /j.ymthe )
Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions

4. Figure 3
Vehicle Optimization for ModRNA Cardiac Tissue Transfection In Vivo
Luc modRNA at a dose of 100 μg (1-mψU)/heart, complexed with different commercially available RNA transfection reagents, was injected directly into myocardium of CFW mice in an open-chest surgery. The IVIS imaging system was used to calculate gene expression at different time points (4, 24, and 48 hr). (A) Representative images of transfected mice 24 hr post-injection directly into myocardium with different commercially available RNA transfection reagents. (B and C) Pharmokinetics (B) or efficient translation (C) of Luc modRNA transfected with different RNA transfection reagents and measured at different time points (4, 24, and 48 hr) using IVIS. Results represent three independent experiments with n = 2 or 3 mice (****p < and ***p < 0.001, one-way ANOVA with Bonferroni post hoc test).
Molecular Therapy  , DOI: ( /j.ymthe )
Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions

5. Figure 4
Optimizing ModRNA Dose for Cardiac Tissue Transfection In Vivo
Different doses (50, 100, and 200 μg) of Luc or Cre modRNA (1-mψU)/heart, delivered in sucrose-citrate buffer, were injected directly into the myocardium of CFW or Rosa26mTmG mice, respectively, in an open-chest surgery. (A) Representative image of transfected CFW mice 24 hr post-intramyocardial injection with different Luc modRNA doses. (B and C) Pharmokinetics (B) or efficient translation (C) of Luc modRNA transfected with different doses and measured at different time points (4, 24, and 48 hr) using IVIS. (D) Representative images of a transfected heart (transfected cells are green and non-transfected cells are red) or heart cross-sections (short axis view) of Rosa26mTmG mouse 24 hr post-injection of 100 μg Cre modRNA directly into myocardium. (E) Quantification of the biodistribution of different doses of Cre modRNA post-transfection in vivo. Results represent two independent experiments with n = 2 or 3 mice (total n = 3–5 mice; **p < 0.01 and *p < 0.05; N.S., not significant; one-way ANOVA with Bonferroni post hoc test).
Molecular Therapy  , DOI: ( /j.ymthe )
Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions

6. Figure 5 Optimized Cardiac Delivery of ModRNA
Cardiac delivery of modRNA with 100% replacement of uridine with 1-mψU yields the highest gene expression and longest pharmacokinetics in comparison to other nucleotide modifications, both in vitro and in vivo. CM transfection in vitro (rat neonatal or hPSC) is optimal with a positively charged transfection reagent, such as RNAiMAX, TransIT, jetMESSENGER, or MessengerMAX, in a concentration of 0.013 μg modRNA/1 mm2 well diameter. For in vivo cardiac delivery in mice, our data show that 100 μg/heart (1.6 μg modRNA/μL in 60 μL total) in sucrose-citrate buffer directly injected into myocardium yields the highest gene expression and covers close to a quarter of the left ventricle of mouse heart.
Molecular Therapy  , DOI: ( /j.ymthe )
Copyright © 2017 The American Society of Gene and Cell Therapy Terms and Conditions